Association between systemic inflammation biomarkers and incident cardiovascular disease in 423,701 individuals: evidence from the UK biobank cohort
Authors' conclusion
There were independent and dose-response relationships between the novel systemic inflammation biomarkers and CVD outcomes. Addition of the inflammation biomarkers including novel inflammation biomarkers showed improved discrimination of the traditional risk prediction model. With accumulated evidence, these biomarkers should be considered for inclusion in risk tools and prevention.
Study context
- Population
- UK Biobank participants free of cardiovascular disease (CVD) at baseline
- Participants
- 423,701 participants
- Exposure
- Systemic inflammation biomarkers and incident CVD
- Outcome
- Incident CVD and main CVD subtypes: ischaemic heart disease (IHD), stroke and HF
Methodological detailsUK Biobank
- UK Biobank
Main finding
As reported in the abstract
Associations of NLR, LMR, PLR, SII and SIRI with CVD, IHD, stroke and HF
- Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), SII and system inflammation response index (SIRI) positively and lymphocyte-to-monocyte ratio (LMR) negatively associated with all four outcomes
- Non-linear relationships for all biomarkers with CVD; linear for NLR, SII and SIRI and non-linear for LMR and PLR with ischaemic heart disease (IHD), stroke and HF
Observational data: associations, not effects.
Further findings
Predictive performance of novel vs more established biomarkers
- All four novel biomarkers had statistically superior predictive performance for CVD, IHD and HF; three of them superior at predicting stroke
Discrimination on adding inflammation markers to classical risk factor model (C-index = 0.702)
- C-index change, CVD
- 0.0069 (95% CI 0.0033 to 0.0107)
- C-index change, IHD
- 0.0054 (95% CI 0.0013 to 0.0095)
- C-index change, HF
- 0.0153 (95% CI 0.0089 to 0.0218)
Original publication
Association between systemic inflammation biomarkers and incident cardiovascular disease in 423,701 individuals: evidence from the UK biobank cohort. Cardiovasc Diabetol. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →